Reliant Investment Partners LLC Makes New $699,000 Investment in Mirum Pharmaceuticals, Inc. $MIRM

Posted by Stanley Muller on Aug 21st, 2026

Reliant Investment Partners LLC purchased a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,975 shares of the company’s stock, valued at approximately $699,000.

Several other institutional investors and hedge funds have also bought and sold shares of MIRM. Contravisory Investment Management Inc. lifted its stake in shares of Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after buying an additional 103 shares in the last quarter. Faithward Advisors LLC boosted its stake in shares of Mirum Pharmaceuticals by 0.5% in the 1st quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after buying an additional 126 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after purchasing an additional 200 shares during the period. Comerica Bank grew its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Finally, Osaic Holdings Inc. grew its position in shares of Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares during the period.

Mirum Pharmaceuticals Trading Down 5.1%

Shares of NASDAQ:MIRM opened at $97.07 on Friday. The business’s fifty day simple moving average is $111.26 and its 200-day simple moving average is $101.98. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $6.30 billion, a PE ratio of -6.67 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $19,221,046.28. This represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the transaction, the senior vice president directly owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,156 shares of company stock valued at $13,763,562 over the last 90 days. Insiders own 8.32% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. TD Cowen decreased their price objective on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Citizens Jmp lowered their target price on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Get Our Latest Report on MIRM

Mirum Pharmaceuticals Company Profile

(Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.